BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $142.72. BNTX has been the subject of several recent research reports.

If an investor was to purchase shares of BNTX stock at the current price level of $114.21/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

Comparing this to the current stock price of $117.25, it appears that BNTX is trading at a premium. Given this premium pricing, unattractive financial performance, and uncertainty revolving around ...

The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...